Novel LZTR1 germline mutation as a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma: a case report
This case report indicates that identification of germline resistance mutations such as <i>LZTR1</i> may be associated with poor response to EGFR TKIs. Furthermore, further characterization of these resistance mutations beyond somatic mutations can aid in development of future therapeutic options, which currently do not exist. It is recommended that germline testing be performed as part of the initial patient workup, if available.
Authors
- Ravi Salgia (ORCID: https://orcid.org/0000-0001-9643-7626)
- Arya Amini (ORCID: https://orcid.org/0000-0002-8311-9159)
- Isa Mambetsariev (ORCID: https://orcid.org/0000-0003-2882-0249)
- Shaira Therese Dingal
- Razmig Babikian
- Wai Park
- Jeremy Fricke (ORCID: https://orcid.org/0000-0003-4684-8114)
- Michelle Afkhami (ORCID: https://orcid.org/0000-0001-5830-6158)
- Giovanny Velasquez
- Pauline Kim
- Reza Nadaf-Rahrov
Institutions
- City Of Hope National Medical Center (US)
- City of Hope (US)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/tlcr-24-723
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07